logo
Analysts Have Conflicting Sentiments on These Energy Companies: Paladin Energy Ltd (OtherPALAF), Whitehaven Coal Limited (OtherWHITF) and HF Sinclair Corporation (DINO)

Analysts Have Conflicting Sentiments on These Energy Companies: Paladin Energy Ltd (OtherPALAF), Whitehaven Coal Limited (OtherWHITF) and HF Sinclair Corporation (DINO)

Analysts have been eager to weigh in on the Energy sector with new ratings on Paladin Energy Ltd (PALAF – Research Report), Whitehaven Coal Limited (WHITF – Research Report) and HF Sinclair Corporation (DINO – Research Report).
Protect Your Portfolio Against Market Uncertainty
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Paladin Energy Ltd (PALAF)
In a report released yesterday, Andrew Hines from Shaw and Partners maintained a Buy rating on Paladin Energy Ltd, with a price target of A$10.10. The company's shares closed last Thursday at $3.78, close to its 52-week low of $3.22.
According to TipRanks.com, Hines is ranked #9068 out of 9437 analysts.
Currently, the analyst consensus on Paladin Energy Ltd is a Strong Buy with an average price target of $5.31, implying a 43.1% upside from current levels. In a report issued on April 16, Citi also maintained a Buy rating on the stock with a A$10.20 price target.
Whitehaven Coal Limited (WHITF)
Goldman Sachs analyst Paul Young maintained a Hold rating on Whitehaven Coal Limited on April 29 and set a price target of A$5.70. The company's shares closed last Thursday at $3.14.
According to TipRanks.com, Young is a 4-star analyst with an average return of 6.7% and a 54.7% success rate. Young covers the Basic Materials sector, focusing on stocks such as Sandfire Resources Limited, Fortescue Metals Group Ltd, and Mineral Resources Limited.
Whitehaven Coal Limited has an analyst consensus of Moderate Buy, with a price target consensus of $4.20, which is a 35.5% upside from current levels. In a report issued on April 15, UBS also downgraded the stock to Hold with a A$5.15 price target.
HF Sinclair Corporation (DINO)
In a report released yesterday, Jason Gabelman from TD Cowen maintained a Hold rating on HF Sinclair Corporation, with a price target of $29.00. The company's shares closed last Thursday at $31.27, close to its 52-week low of $29.85.
According to TipRanks.com, Gabelman is a 4-star analyst with an average return of 4.9% and a 50.0% success rate. Gabelman covers the NA sector, focusing on stocks such as Calumet Specialty Products, Par Pacific Holdings, and Marathon Petroleum.
Currently, the analyst consensus on HF Sinclair Corporation is a Moderate Buy with an average price target of $41.22, implying a 32.5% upside from current levels. In a report issued on April 16, Barclays also maintained a Hold rating on the stock with a $29.00 price target.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Why Is Helius Medical Tech Stock (HSDT) Up 100% Today?
Why Is Helius Medical Tech Stock (HSDT) Up 100% Today?

Business Insider

time15 minutes ago

  • Business Insider

Why Is Helius Medical Tech Stock (HSDT) Up 100% Today?

Helius Medical Technologies (HSDT) stock surged on Wednesday after the neurotech company announced an authorized claim for payment for its Portable Neuromodulation Stimulator (PoNS) from CVS Health (CVS) -owned Aetna Healthcare. This is the third time a major healthcare provider has offered to cover PoNS for a patient. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Dane Andreeff, President and CEO of Helius Medical Tech, said, 'We are actively pursuing broader in-network coverage for PoNS at list price from major commercial payers, while continuing to negotiate reimbursement on a case-by-case basis.' PoNS is an orally applied therapy that delivers neurostimulation via a non-implantable mouthpiece. HSDT stock rocketed 98.82% during pre-market trading on Wednesday. That's a welcome change from its 91.50% drop year-to-date and 94.88% fall over the past 12 months. Is Helius Medical Technologies Stock a Buy, Sell, or Hold? Wall Street's coverage of Helius Medical Technologies is thin, but TipRanks' AI analyst Spark fills that gap. Spark rates HSDT stock an Underperform (38) with a $1 price target. The AI analyst cites 'significant financial and operational challenges' as reasons for this rating and price.

Catheter Precision Stock (VTAK) Rockets 170% on a Delayed Investor Reaction
Catheter Precision Stock (VTAK) Rockets 170% on a Delayed Investor Reaction

Business Insider

time30 minutes ago

  • Business Insider

Catheter Precision Stock (VTAK) Rockets 170% on a Delayed Investor Reaction

Catheter Precision (VTAK) stock surged on Wednesday after the medical device company announced the first purchase order for its VIVO product. This is a non-invasive 3D imaging system to identify the origin of ventricular arrhythmias pre-procedure. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Catheter Precision reached an agreement with Sahlgrenska University Hospital for its VIVO devices. That's a major win for the company as this is Sweden's largest hospital with over 350,000 patients per year. It also has the largest ventricular ablation program in the region. David Jenkins, CEO of Catheter Precision, said, 'Creating strong partnerships with teaching hospitals enables new physicians to be trained with our products and creating a new opportunity for future sales when that physician leaves the teaching institution.' VTAK Stock Movement Today While the VIVO sales agreement was announced on Monday, investors only recently took notice of it. This delayed reaction resulted in a 170.1% rally in pre-market trading on Wednesday. This easily erases the stock's 49.69% drop year-to-date, but still leaves it well below its 52-week high of $6.40. Is Catheter Precision Stock a Buy, Sell, or Hold? Wall Street's coverage of Catheter Precision is lacking, but TipRanks' AI analyst, Spark, fills in that gap. Spark rates VTAK stock a Neutral (41) with no price target, citing 'significant financial challenges with persistent losses and negative cash flows' as reasons for this stance.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store